Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know

Bristol Myers Squibb (BMY) is receiving significant investor attention. The stock has declined 6.1% over the past month, underperforming the S&P 500. However, the company maintains a Zacks Rank #2 (Buy) rating based on positive earnings estimate revisions and strong recent performance, with the stock trading at a valuation discount to peers. BMY beat consensus estimates in the last four quarters with an EPS surprise of +28.3% and revenue surprise of +11.15%.